• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • e‑newsletter
    • e‑newsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

EndeavorRx

Digital therapeutics pioneer Akili Interactive Labs goes public, raising $150M+; trades down 49% first day

August 23, 2022 by SharpBrains

Akili Inter­ac­tive is the lat­est com­pa­ny to go pub­lic via SPAC deal (Boston Busi­ness Journal):

Boston’s Akili Inter­ac­tive Labs Inc. is the lat­est Mass­a­chu­setts-based com­pa­ny to go pub­lic after com­plet­ing a reverse merg­er — in a year of mar­ket tur­moil that saw few local firms pass­ing the thresh­old between pri­vate and pub­lic status.

Shares of Akili start­ed trad­ing on Mon­day on the Nas­daq Cap­i­tal Mar­ket under the new tick­er sym­bol “AKLI” after the com­pa­ny com­plet­ed its pre­vi­ous­ly announced reverse merg­er with Social Cap­i­tal Suvret­ta Hold­ings Corp. I (Nas­daq: DNAA), a spe­cial pur­pose acqui­si­tion com­pa­ny, or SPAC. [Read more…] about Dig­i­tal ther­a­peu­tics pio­neer Akili Inter­ac­tive Labs goes pub­lic, rais­ing $150M+; trades down 49% first day

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: Akili Interactive Labs, AKLI, cognitive, Cognitive-impairment, digital medicine, digital therapeutics, DNAA, EndeavorRx, neuropsychiatric, neuropsychiatric diseases, SPAC

Digital therapeutics pioneer Akili Interactive plans to go public in mid-2022 at a $1B valuation

January 26, 2022 by SharpBrains

Pal­i­hapi­tiya-Led SPAC to Merge With Akili in $1 Bil­lion Deal (Bloomberg):

Akili Inter­ac­tive, a start­up that has devel­oped a video game to help treat atten­tion-deficit dis­or­ders in kids, has agreed to go pub­lic through a merg­er with one of Chamath Palihapitiya’s blank-check companies.

The deal, which con­firms a Bloomberg News report, val­ues the com­bined enti­ty at about $1 bil­lion, Akili and Social Cap­i­tal Suvret­ta Hold­ings Corp. I said in a state­ment seen by Bloomberg. It will pro­vide as much as $412 mil­lion in gross cash pro­ceeds, the com­pa­nies said. [Read more…] about Dig­i­tal ther­a­peu­tics pio­neer Akili Inter­ac­tive plans to go pub­lic in mid-2022 at a $1B valuation

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Attention & ADD/ADHD, Brain/ Mental Health, Technology & Innovation Tagged With: adhd, Akili Interactive, attention deficit hyperactivity disorder, Chamath Palihapitiya, cognitive-impairments, digital therapeutics, EndeavorRx, FDA, neuropsychiatric, neuropsychiatric treatment, Social Capital Suvretta Holdings, treatment, video-game

Akili Interactive Labs raises $160M in equity and debt to transform cognitive healthcare via prescription videogame treatments

May 26, 2021 by SharpBrains

Akili rais­es $110m to build its dig­i­tal ther­a­peu­tics pipeline (phar­mafo­rum):

Endeav­or­Rx became the first and so far only approved pre­scrip­tion video game treat­ment in the US when it was cleared by the FDA last year to treat atten­tion-deficit hyper­ac­tiv­i­ty dis­or­der (ADHD), and has also been giv­en a green light in Europe. [Read more…] about Akili Inter­ac­tive Labs rais­es $160M in equi­ty and debt to trans­form cog­ni­tive health­care via pre­scrip­tion videogame treatments

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Attention & ADD/ADHD, Brain/ Mental Health, Technology & Innovation Tagged With: adhd, Akili, Akili Inter­ac­tive Labs, attention deficit hyperactivity disorder, cognitive healthcare, cognitive--disorders, digital therapeutics, EndeavorRx, FDA, Neuberger Berman, prescription digital therapeutics, videogame

FDA clears first videogame to be prescribed to kids with ADHD: EndeavorRx by Akili Interactive Labs

June 18, 2020 by SharpBrains

Screen­shot of EndeavorRx

In a land­mark deci­sion, FDA green­lights a video game for kids with ADHD (STAT):

The Food and Drug Admin­is­tra­tion on Mon­day for the first time gave a green light to a game-based ther­a­peu­tic: a video game meant to be pre­scribed to kids with ADHD.

The game, known as Endeav­or­Rx and devel­oped by Boston-based Akili Inter­ac­tive Labs, can now be mar­ket­ed as a way to improve atten­tion func­tion in kids with ADHD as mea­sured by com­put­er­ized test­ing. Physi­cians can pre­scribe it to chil­dren between the ages of 8 and 12 who have an ADHD diag­no­sis and have demon­strat­ed an issue with attention.

The FDA’s move is a land­mark deci­sion in the emerg­ing dig­i­tal ther­a­peu­tics sec­tor: In addi­tion to being the first game to be mar­ket­ed as a ther­a­py for any type of con­di­tion, Endeav­or­Rx is the first dig­i­tal ther­a­peu­tic meant to improve symp­toms asso­ci­at­ed with ADHD, the FDA’s announce­ment said…The game was born in the Uni­ver­si­ty of Cal­i­for­nia, San Fran­cis­co lab of neu­ro­sci­en­tist Adam Gaz­za­ley, and was licensed out by Akili, which pol­ished and test­ed the game in clin­i­cal tri­als. Akili spent the past two years wait­ing on a reg­u­la­to­ry deci­sion from the FDA.

[Read more…] about FDA clears first videogame to be pre­scribed to kids with ADHD: Endeav­or­Rx by Akili Inter­ac­tive Labs

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: 510(k), Adam Gazzaley, adhd, Akili Interactive Labs, computerized testing, De Novo, digital therapeutics, EndeavorRx, FDA, game-based therapeutic, TOVA, videogame

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Subscribe to our e-newsletter

* indicates required

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2023 SharpBrains. All Rights Reserved - Privacy Policy